research and development pipeline to treat cancer and other serious diseases  cyclacel home  about cyclacel pharmaceuticals  research and development pipeline about cyclacel pharmaceuticals research and development pipeline we are a biopharmaceutical company dedicated to the development and commercialization of novel mechanismtargeted drugs to treat human cancers and other serious diseases our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates our clinical development priorities are focused on sapacitabine in the following indications acute myeloid leukemia or aml in the elderly myelodysplastic syndromes or mds and nonsmall cell lung cancer or nsclc in january   the company opened enrollment of the seamless pivotal phase  trial for the companys sapacitabine oral capsules as a frontline treatment of elderly patients aged  years or older with newly diagnosed aml who are not candidates for intensive induction chemotherapy seamless is a registrationdirected clinical trial and is conducted under a special protocol assessment or spa agreement with the us food and drug administration or fda seamless is a randomized study against an active control drug with the primary objective of demonstrating an improvement in overall survival after reviewing data from a pilot study of the active arm of the study the seamless data safety monitoring board or dsmb recommended that the trial continue as planned the company has advanced two additional product candidates seliciclib in phase  for nsclc and nasopharyngeal cancer or npc and cyc in phase  clinical development the combination of sapacitabine with seliciclib is also being evaluated in a phase  clinical trial the company will determine the feasibility of pursuing further development andor partnering these assets depending on the availability of funding and further clinical data   about cyclacel pharmaceuticals company overview research and development pipeline people management team board of directors scientific advisory board alliances and collaborations alerting service cyclacel pharmaceuticals inc  biopharmaceutical company developing cell cycle control cancer therapies cell cycle pioneers improving patients healthcare with orally available innovative medicines cyclacel pharmaceuticals inc nasdaq cycc nasdaq cyccp is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases our pipeline applying its core strength in cell cycle biology cyclacel is advancing a pipeline of orally available small molecule investigational drugs designed to stop uncontrolled cell division sapacitabine our lead drug candidate is being evaluated in the seamless pivotal phase  trial in elderly patients with acute myeloid leukemia under a special protocol assessment agreement with the us food and drug administration for more information on our investigational drug programs and clinical trials please go to the research  development tab above learn more about our clinical trials sapacitabine cyc an oral nucleoside analogue prodrug that acts through a novel mechanism seliciclib cyc a novel firstinclass orally available cyclin dependent kinase cdk inhibitor cyc a highlyselective orallyavailable nd generation inhibitor of cyclin dependent kinases cdk  and  perspectives sapacitabine patient seliciclib patient investigator details common stock info nasdaqcm cycc us delayed at least  minutes provided by esignal healtheo presents exchange  a conversation with spiro rombotis from cyclacel acute myeloid leukemia watch the video on the healtheo website cyclin dependent kinase cdk and aurora kinase ak inhibitors  cyclacel rd for anticancer drugs acting on cell cycle home  research  development research  development research  development overview cyclacel is a pioneer company in the field of cell cycle biology and our goal is to develop small molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases particularly those of high unmet medical need with a vision to improve patient healthcare with orally available innovative medicines we have generated several families of anticancer drugs that act on the cell cycle including sapacitabine seliciclib and cyc clinical drug pipeline research  development programs clinical oncology programs sapacitabine cyc seliciclib cyc cyc other programs science and technology cell cycle in cancer clinical trials publications investors  media overview home  investors  media  mo    mo    yr stock quote nasdaq cycc us price  change   day high  day low  volume   pm et on jul   delayed at least  minutes provided by esignal investors  media overview we are committed to serving the best interests of our shareholders you will find key shareholder information and financial reports available to help put cyclacel pharmaceuticals incs financial performance into perspective recent releases jul   cyclacel announces closing of  million underwritten public offering and full exercise of overallotment option jul   cyclacel announces pricing of  million underwritten public offering view all  events  presentations may   at  pm et first quarter  financial results mar   at  pm et fourth quarter  financial results view all  annual reports  annual report view all  investors  media corporate governance board of directors committee composition management team common stock information news sec filings analysts corporate presentations  events corporate factsheet annual reports archive request investor pack alerting service investor tools share this on delicious digg facebook linkedin twitter what is this overview of the company and its pharmaceutical efforts to control cancer and other serious diseases  cyclacel home  about cyclacel pharmaceuticals  company overview about cyclacel pharmaceuticals company overview cyclacel pharmaceuticals inc is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases professor sir david lane a recognized leader in the field of tumor suppressor biology who discovered the p protein founded the company in  in  cyclacel pharmaceuticals was joined by professor david glover a recognized leader in the mechanism of mitosis or cell division who discovered among other cell cycle targets the mitotic kinases polo and aurora enzymes that act in the mitosis phase of the cell cycle sapacitabine cyc cyclacels most advanced product candidate is the subject of seamless a phase  trial which has completed enrollment and is being conducted under an spa with the fda as frontline treatment for acute myeloid leukemia aml in the elderly and other indications including myelodysplastic syndromes mds cyclacels pipeline includes an oral regimen of seliciclib in combination with sapacitabine in a phase  study of patients with homologous recombination hr repairdeficient breast ovarian and pancreatic cancers including brca positive tumors and cyc a novel cdk inhibitor in a phase  study of patients with solid tumors with potential utility in both hematological malignancies and solid tumors cyclacels strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates cyclacel pharmaceuticals corporate headquarters are in berkeley heights new jersey where our business development and medical and regulatory functions are also located the companys primary research facility is located in dundee scotland dundee is the main location of our translational research and preclinical activities about cyclacel pharmaceuticals company overview research and development pipeline people management team board of directors scientific advisory board alliances and collaborations alerting service contact cyclacel corporate headquarters in berkeley heights new jersey research and preclinical activities in dundee scotland home  contact about cyclacel pharmaceuticals contact department contact information  alerting service thank you for your interest in cyclacel pharmaceuticals corporate headquarters  connell drive  berkeley heights nj  united states of america t     f     european operations  james lindsay place dundee dd jj united kingdom t     f       to request information please complete and submit the following form fields with a  must be completed before sending the form full name email phone number fax number street city stateprovince zippostal code country please provide us with details of your inquiry department contact information corporate communicationsinvestor relations t     f     email ircyclacelcom human resources t     f     email infocyclacelcom strategic alliances and business development t     f     email bdevcyclacelcom alerting service please fill out this form to automatically receive cyclacel pharmaceuticals inc financial information by email   about cyclacel pharmaceuticals company overview research and development pipeline people management team board of directors scientific advisory board alliances and collaborations alerting service cyclacel  wikipedia cyclacel from wikipedia the free encyclopedia   redirected from cyclacel pharmaceuticals inc jump to navigation search cyclacel pharmaceuticals inc type public nasdaq cycc industry biotechnology founded  headquarters berkeley heights new jersey us key people spiro rombotis ceo david p lane founder products seliciclib cyc sapacitabine cyc aurora kinase inhibitors cyc net income us  million  number of employees   website httpwwwcyclacelcom cyclacel pharmaceuticals inc is a biotechnology firm based in dundee scotland and short hills new jersey developing cancer drugs and treatments cyclacel was founded in  by professor david lane merlin ventures and cancer research campaign technology with the university of dundee and the university of glasgow major shareholders include goldman sachs group tang capital management redmile group and ayer capital management the firm is developing mechanismtargeted drugs to help in the fight of cancer and other serious illness such as diabetes and hiv contents  company overview  expansion  staff  see also  notes company overviewedit cyclacel pharmaceuticals inc is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases professor sir david lane a recognized leader in the field of tumor suppressor biology who discovered the p protein founded the company in  in  cyclacel pharmaceuticals was joined by professor david glover a recognized leader in the mechanism of mitosis or cell division who discovered among other cell cycle targets the mitotic kinases polo and aurora enzymes that act in the mitosis phase of the cell cycle three product candidates are currently in clinical development sapacitabine cyc a cell cycle modulating nucleoside analogue is in phase  development for the treatment of acute myeloid leukemia aml in the elderly under a special protocol assessment agreement with the us food and drug administration and phase  studies for myelodysplastic syndromes lung cancer and chronic lymphocytic leukemia seliciclib cyc or rroscovitine a cdk cyclin dependent kinase inhibitor is in phase  studies for the treatment of lung cancer and nasopharyngeal cancer and in a phase  trial in combination with sapacitabine cyc an aurora kinase and vegfr inhibitor is in a phase  trial in patients with solid tumors cyclacel pharmaceuticals strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates cyclacel pharmaceuticals align pharmaceuticals subsidiary markets directly in the us xclair cream for radiation dermatitis numoisyn® liquid and numoisyn® lozenges for xerostomia expansionedit after becoming the first european spinout company to raise over  million in private equity the company had to pull out of a stock market listing in july  cyclacel completed a reverse merger with xcyte therapies in december  to acquire nasdaq listing this allowed cyclacel to take advantage of its adopted nasdaq listing by raising an additional  million in april  through a private placement of stock and warrants staffedit this section does not cite any sources please help improve this section by adding citations to reliable sources unsourced material may be challenged and removed november  learn how and when to remove this template message spiro rombotis president and chief executive officer paul mcbarron executive vice president finance and chief operating officer judy chiao vice president clinical development and regulatory affairs gill christie director human resources susan davis associate director business development professor david glover frse chief scientist polgen development see alsoedit pharmaceutical industry in the united kingdom notesedit  cyclacel completes  million private placement bioportfolio  archived from the original on april   retrieved january     nick bevens  cyclacel gets a £m bailout the scotsman uk retrieved october     xcyte sells off assets puget sound business journal december   retrieved december    v t e university of dundee governance chancellor the lord patel rector mark beaumont principal sir peter downes general council university court senatus academicus students representative council history medical schools mills observatory telecommunications research establishment university of st andrews academic centre for dermatology and genetic medicine centre for energy petroleum and mineral law and policy centre for gene regulation and expression division of signal transduction therapy duncan of jordanstone college of art and design medical school school of law facilities botanic garden darcy thompson zoology museum dundee royal infirmary formerly ninewells hospital maryfield hospital formerly perth royal infirmary student life students association shinty club tayforth uotc east of scotland universities air squadron undergraduate gown people mary ann baxter cofounder academics alumni chancellors rectors related topics caird hall canongate books cyclacel dictionary of the scots language dundee cell products dundee university press until  dundee international book prize  category  commons v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category retrieved from httpsenwikipediaorgwindexphptitlecyclaceloldid categories pharmaceutical companies of scotlandcompanies based in dundee establishments in scotlandpharmaceutical companies established in pharmaceutical companies based in new jerseyscience and technology in dundeehidden categories use mdy dates from april pages using deprecated image syntaxarticles needing additional references from november all articles needing additional references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  november  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view cyclacel  wikipedia cyclacel from wikipedia the free encyclopedia   redirected from cyclacel pharmaceuticals inc jump to navigation search cyclacel pharmaceuticals inc type public nasdaq cycc industry biotechnology founded  headquarters berkeley heights new jersey us key people spiro rombotis ceo david p lane founder products seliciclib cyc sapacitabine cyc aurora kinase inhibitors cyc net income us  million  number of employees   website httpwwwcyclacelcom cyclacel pharmaceuticals inc is a biotechnology firm based in dundee scotland and short hills new jersey developing cancer drugs and treatments cyclacel was founded in  by professor david lane merlin ventures and cancer research campaign technology with the university of dundee and the university of glasgow major shareholders include goldman sachs group tang capital management redmile group and ayer capital management the firm is developing mechanismtargeted drugs to help in the fight of cancer and other serious illness such as diabetes and hiv contents  company overview  expansion  staff  see also  notes company overviewedit cyclacel pharmaceuticals inc is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases professor sir david lane a recognized leader in the field of tumor suppressor biology who discovered the p protein founded the company in  in  cyclacel pharmaceuticals was joined by professor david glover a recognized leader in the mechanism of mitosis or cell division who discovered among other cell cycle targets the mitotic kinases polo and aurora enzymes that act in the mitosis phase of the cell cycle three product candidates are currently in clinical development sapacitabine cyc a cell cycle modulating nucleoside analogue is in phase  development for the treatment of acute myeloid leukemia aml in the elderly under a special protocol assessment agreement with the us food and drug administration and phase  studies for myelodysplastic syndromes lung cancer and chronic lymphocytic leukemia seliciclib cyc or rroscovitine a cdk cyclin dependent kinase inhibitor is in phase  studies for the treatment of lung cancer and nasopharyngeal cancer and in a phase  trial in combination with sapacitabine cyc an aurora kinase and vegfr inhibitor is in a phase  trial in patients with solid tumors cyclacel pharmaceuticals strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates cyclacel pharmaceuticals align pharmaceuticals subsidiary markets directly in the us xclair cream for radiation dermatitis numoisyn® liquid and numoisyn® lozenges for xerostomia expansionedit after becoming the first european spinout company to raise over  million in private equity the company had to pull out of a stock market listing in july  cyclacel completed a reverse merger with xcyte therapies in december  to acquire nasdaq listing this allowed cyclacel to take advantage of its adopted nasdaq listing by raising an additional  million in april  through a private placement of stock and warrants staffedit this section does not cite any sources please help improve this section by adding citations to reliable sources unsourced material may be challenged and removed november  learn how and when to remove this template message spiro rombotis president and chief executive officer paul mcbarron executive vice president finance and chief operating officer judy chiao vice president clinical development and regulatory affairs gill christie director human resources susan davis associate director business development professor david glover frse chief scientist polgen development see alsoedit pharmaceutical industry in the united kingdom notesedit  cyclacel completes  million private placement bioportfolio  archived from the original on april   retrieved january     nick bevens  cyclacel gets a £m bailout the scotsman uk retrieved october     xcyte sells off assets puget sound business journal december   retrieved december    v t e university of dundee governance chancellor the lord patel rector mark beaumont principal sir peter downes general council university court senatus academicus students representative council history medical schools mills observatory telecommunications research establishment university of st andrews academic centre for dermatology and genetic medicine centre for energy petroleum and mineral law and policy centre for gene regulation and expression division of signal transduction therapy duncan of jordanstone college of art and design medical school school of law facilities botanic garden darcy thompson zoology museum dundee royal infirmary formerly ninewells hospital maryfield hospital formerly perth royal infirmary student life students association shinty club tayforth uotc east of scotland universities air squadron undergraduate gown people mary ann baxter cofounder academics alumni chancellors rectors related topics caird hall canongate books cyclacel dictionary of the scots language dundee cell products dundee university press until  dundee international book prize  category  commons v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category retrieved from httpsenwikipediaorgwindexphptitlecyclaceloldid categories pharmaceutical companies of scotlandcompanies based in dundee establishments in scotlandpharmaceutical companies established in pharmaceutical companies based in new jerseyscience and technology in dundeehidden categories use mdy dates from april pages using deprecated image syntaxarticles needing additional references from november all articles needing additional references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  november  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view cyclacel  wikipedia cyclacel from wikipedia the free encyclopedia   redirected from cyclacel pharmaceuticals inc jump to navigation search cyclacel pharmaceuticals inc type public nasdaq cycc industry biotechnology founded  headquarters berkeley heights new jersey us key people spiro rombotis ceo david p lane founder products seliciclib cyc sapacitabine cyc aurora kinase inhibitors cyc net income us  million  number of employees   website httpwwwcyclacelcom cyclacel pharmaceuticals inc is a biotechnology firm based in dundee scotland and short hills new jersey developing cancer drugs and treatments cyclacel was founded in  by professor david lane merlin ventures and cancer research campaign technology with the university of dundee and the university of glasgow major shareholders include goldman sachs group tang capital management redmile group and ayer capital management the firm is developing mechanismtargeted drugs to help in the fight of cancer and other serious illness such as diabetes and hiv contents  company overview  expansion  staff  see also  notes company overviewedit cyclacel pharmaceuticals inc is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases professor sir david lane a recognized leader in the field of tumor suppressor biology who discovered the p protein founded the company in  in  cyclacel pharmaceuticals was joined by professor david glover a recognized leader in the mechanism of mitosis or cell division who discovered among other cell cycle targets the mitotic kinases polo and aurora enzymes that act in the mitosis phase of the cell cycle three product candidates are currently in clinical development sapacitabine cyc a cell cycle modulating nucleoside analogue is in phase  development for the treatment of acute myeloid leukemia aml in the elderly under a special protocol assessment agreement with the us food and drug administration and phase  studies for myelodysplastic syndromes lung cancer and chronic lymphocytic leukemia seliciclib cyc or rroscovitine a cdk cyclin dependent kinase inhibitor is in phase  studies for the treatment of lung cancer and nasopharyngeal cancer and in a phase  trial in combination with sapacitabine cyc an aurora kinase and vegfr inhibitor is in a phase  trial in patients with solid tumors cyclacel pharmaceuticals strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates cyclacel pharmaceuticals align pharmaceuticals subsidiary markets directly in the us xclair cream for radiation dermatitis numoisyn® liquid and numoisyn® lozenges for xerostomia expansionedit after becoming the first european spinout company to raise over  million in private equity the company had to pull out of a stock market listing in july  cyclacel completed a reverse merger with xcyte therapies in december  to acquire nasdaq listing this allowed cyclacel to take advantage of its adopted nasdaq listing by raising an additional  million in april  through a private placement of stock and warrants staffedit this section does not cite any sources please help improve this section by adding citations to reliable sources unsourced material may be challenged and removed november  learn how and when to remove this template message spiro rombotis president and chief executive officer paul mcbarron executive vice president finance and chief operating officer judy chiao vice president clinical development and regulatory affairs gill christie director human resources susan davis associate director business development professor david glover frse chief scientist polgen development see alsoedit pharmaceutical industry in the united kingdom notesedit  cyclacel completes  million private placement bioportfolio  archived from the original on april   retrieved january     nick bevens  cyclacel gets a £m bailout the scotsman uk retrieved october     xcyte sells off assets puget sound business journal december   retrieved december    v t e university of dundee governance chancellor the lord patel rector mark beaumont principal sir peter downes general council university court senatus academicus students representative council history medical schools mills observatory telecommunications research establishment university of st andrews academic centre for dermatology and genetic medicine centre for energy petroleum and mineral law and policy centre for gene regulation and expression division of signal transduction therapy duncan of jordanstone college of art and design medical school school of law facilities botanic garden darcy thompson zoology museum dundee royal infirmary formerly ninewells hospital maryfield hospital formerly perth royal infirmary student life students association shinty club tayforth uotc east of scotland universities air squadron undergraduate gown people mary ann baxter cofounder academics alumni chancellors rectors related topics caird hall canongate books cyclacel dictionary of the scots language dundee cell products dundee university press until  dundee international book prize  category  commons v t e pharmaceutical and biotechnology industry in the united kingdom manufacturing in the united kingdom economy of the united kingdom companies current aah pharmaceuticals alliance boots astex astrazeneca medimmune btg cyclacel dechra pharmaceuticals ge healthcare genus glaxosmithkline hikma pharmaceuticals indivior macfarlan smith norbrook group oxford biomedica pfizer uk phytopharm proximagen shire silence therapeutics tbs gb unipath vectura group vernalis viiv healthcare defunct allen  hanburys amersham beecham group cambridge antibody technology celltech chiroscience distillers company fisons glaxo wellcome ici reliant pharmaceuticals renovo zeneca government and regulatory bodies commission on human medicines department of health european directorate for the quality of medicines european medicines agency medicines and healthcare products regulatory agency national collaborating centre for mental health national patient safety agency pharmaceutical price regulation scheme pharmaceutical society of northern ireland general pharmaceutical council scottish medicines consortium veterinary medicines directorate industry and professional bodies association of the british pharmaceutical industry chemical industries association european federation of biotechnology european federation of pharmaceutical industries and associations faculty of pharmaceutical medicine pharmacists defence association royal pharmaceutical society of great britain worshipful society of apothecaries books and journals bandolier bad pharma  british national formulary british national formulary for children monthly index of medical specialities side effects  the pharmaceutical journal other british approved name british pharmacopoeia drugscope european and developing countries clinical trials partnership european pharmacopoeia list of worlds largest pharmaceutical companies pharmaceutical services negotiating committee wellcome trust category retrieved from httpsenwikipediaorgwindexphptitlecyclaceloldid categories pharmaceutical companies of scotlandcompanies based in dundee establishments in scotlandpharmaceutical companies established in pharmaceutical companies based in new jerseyscience and technology in dundeehidden categories use mdy dates from april pages using deprecated image syntaxarticles needing additional references from november all articles needing additional references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  november  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view cyclacel pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports cyclacel pharmaceuticals inc  product pipeline review  cyclacel pharmaceuticals inc  product pipeline review   wgr  october  global  pages global markets direct description table of content sample report enquiry before buy related reports cyclacel pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘cyclacel pharmaceuticals inc  product pipeline review  ’ provides an overview of the cyclacel pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of cyclacel pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of cyclacel pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of cyclacel pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the cyclacel pharmaceuticals inc’s pipeline productsreasons to buy evaluate cyclacel pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of cyclacel pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the cyclacel pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of cyclacel pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of cyclacel pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of cyclacel pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures cyclacel pharmaceuticals inc snapshot cyclacel pharmaceuticals inc overview key information key facts cyclacel pharmaceuticals inc  research and development overview key therapeutic areas cyclacel pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities cyclacel pharmaceuticals inc  pipeline products glance cyclacel pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities cyclacel pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities cyclacel pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities cyclacel pharmaceuticals inc  drug profiles sapacitabine product description mechanism of action rd progress seliciclib product description mechanism of action rd progress sapacitabine  seliciclib product description mechanism of action rd progress cyc product description mechanism of action rd progress cyc product description mechanism of action rd progress cyc product description mechanism of action rd progress small molecule to inhibit cdks for hivaids autoimmune disorders and inflammation product description mechanism of action rd progress cyclacel pharmaceuticals inc  pipeline analysis cyclacel pharmaceuticals inc  pipeline products by target cyclacel pharmaceuticals inc  pipeline products by route of administration cyclacel pharmaceuticals inc  pipeline products by molecule type cyclacel pharmaceuticals inc  pipeline products by mechanism of action cyclacel pharmaceuticals inc  recent pipeline updates cyclacel pharmaceuticals inc  dormant projects cyclacel pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablescyclacel pharmaceuticals inc key information cyclacel pharmaceuticals inc key facts cyclacel pharmaceuticals inc  pipeline by indication  cyclacel pharmaceuticals inc  pipeline by stage of development  cyclacel pharmaceuticals inc  monotherapy products in pipeline  cyclacel pharmaceuticals inc  combination treatment modalities in pipeline  cyclacel pharmaceuticals inc  phase iii  cyclacel pharmaceuticals inc  phase ii  cyclacel pharmaceuticals inc  phase i  cyclacel pharmaceuticals inc  preclinical  cyclacel pharmaceuticals inc  pipeline by target  cyclacel pharmaceuticals inc  pipeline by route of administration  cyclacel pharmaceuticals inc  pipeline by molecule type  cyclacel pharmaceuticals inc  pipeline products by mechanism of action  cyclacel pharmaceuticals inc  recent pipeline updates  cyclacel pharmaceuticals inc  dormant developmental projects cyclacel pharmaceuticals inc other locations cyclacel pharmaceuticals inc subsidiaries list of figurescyclacel pharmaceuticals inc  pipeline by top  indication  cyclacel pharmaceuticals inc  pipeline by stage of development  cyclacel pharmaceuticals inc  monotherapy products in pipeline  cyclacel pharmaceuticals inc  pipeline by top  target  cyclacel pharmaceuticals inc  pipeline by top  route of administration  cyclacel pharmaceuticals inc  pipeline by top  molecule type  cyclacel pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send cyclacel pharmaceuticals inc announces closing of  million underwritten offering nasdaqcycc             share this on delicious digg facebook linkedin twitter what is this « previous release  next release » april   cyclacel pharmaceuticals inc announces closing of  million underwritten offering berkeley heights nj april   globe newswire  cyclacel pharmaceuticals inc nasdaqcycc nasdaqcyccp cyclacel or the company today announced that it has closed the previously announced underwritten offering of  shares of its common stock at a price to the public of  per share for gross proceeds of approximately  million in addition the company has granted the underwriters a day option to purchase an additional  shares of common stock to cover overallotments if any the net proceeds after underwriting discounts and commissions and other estimated fees and expenses payable by the company are approximately  million the company intends to use the proceeds from this offering for the continued development of its most advanced product candidate sapacitabine in a randomized study of patients with myelodysplastic syndromes and general corporate purposes laidlaw  company uk ltd is the sole bookrunning manager for the offering the securities described above were sold by cyclacel pursuant to a shelf registration statement previously filed with the securities and exchange commission and which is effective a prospectus supplement relating to the offering dated april   is available on the secs website at httpwwwsecgov electronic copies of the prospectus supplement and accompanying prospectus may be obtained from the offices of laidlaw  company uk ltd  fifth avenue th floor new york ny  telephone  this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdictionabout cyclacel pharmaceuticals inc cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases sapacitabine cyclacels most advanced product candidate is the subject of seamless a phase  trial being conducted under an spa with the fda as frontline treatment for acute myeloid leukemia aml in the elderly and other studies for myelodysplastic syndromes mds chronic lymphocytic leukemia cll and solid tumors including breast lung ovarian and pancreatic cancer and in particular those carrying gbrca mutations cyclacels strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates please visit wwwcyclacelcom for additional informationforwardlooking statements this news release contains certain forwardlooking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forwardlooking statements such forwardlooking statements include statements regarding among other things the efficacy safety and intended utilization of cyclacels product candidates the conduct and results of future clinical trials plans regarding regulatory filings future research and clinical trials and plans regarding partnering activities factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety andor efficacy in largerscale or later clinical trials trials may have difficulty enrolling cyclacel may not obtain approval to market its product candidates the risks associated with reliance on outside financing to meet capital requirements and the risks associated with reliance on collaborative partners for further clinical trials development and commercialization of product candidates you are urged to consider statements that include the words may will would could should believes estimates projects potential expects plans anticipates intends continues forecast designed goal or the negative of those words or other comparable words to be uncertain and forwardlooking for a further list and description of the risks and uncertainties the company faces please refer to our most recent annual report on form k and other periodic and other filings we file with the securities and exchange commission and are available at wwwsecgov such forwardlooking statements are current only as of the date they are made and we assume no obligation to update any forwardlooking statements whether as a result of new information future events or otherwise  copyright  cyclacel pharmaceuticals inc all rights reserved the cyclacel logo and cyclacel® are trademarks of cyclacel pharmaceuticals inccontact contacts for cyclacel pharmaceuticals inc company paul mcbarron   pmcbarroncyclacelcom investor relations russo partners llc robert flamm   robertflammrussopartnersllccom close window  back to top delicious digg facebook linkedin twitter copyright  cyclacel pharmaceuticals inc market report cyclacel pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing cyclacel pharmaceuticals inc  product pipeline review   aug    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs cyclacel pharmaceuticals inc  product pipeline review   provides an overview of the cyclacel pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of cyclacel pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasereport scopethe report provides brief overview of cyclacel pharmaceuticals inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of cyclacel pharmaceuticals incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the cyclacel pharmaceuticals incs pipeline productsreasons to get this reportevaluate cyclacel pharmaceuticals incs strategic position with total access to detailed information on its product pipelineassess the growth potential of cyclacel pharmaceuticals inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the cyclacel pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of cyclacel pharmaceuticals inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of cyclacel pharmaceuticals incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of cyclacel pharmaceuticals inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contents list of tables list of figures cyclacel pharmaceuticals inc snapshot cyclacel pharmaceuticals inc overview key information key facts cyclacel pharmaceuticals inc  research and development overview key therapeutic areas cyclacel pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities cyclacel pharmaceuticals inc  pipeline products glance cyclacel pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities cyclacel pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities cyclacel pharmaceuticals inc  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities discovery productscombination treatment modalities cyclacel pharmaceuticals inc  drug profiles sapacitabine product description mechanism of action rd progress seliciclib product description mechanism of action rd progress sapacitabine  seliciclib product description mechanism of action rd progress cyc product description mechanism of action rd progress cyc product description mechanism of action rd progress cyclacel pharmaceuticals inc  pipeline analysis cyclacel pharmaceuticals inc  pipeline products by target cyclacel pharmaceuticals inc  pipeline products by route of administration cyclacel pharmaceuticals inc  pipeline products by molecule type cyclacel pharmaceuticals inc  pipeline products by mechanism of action cyclacel pharmaceuticals inc  recent pipeline updates cyclacel pharmaceuticals inc  dormant projects cyclacel pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablescyclacel pharmaceuticals inc key information cyclacel pharmaceuticals inc key facts cyclacel pharmaceuticals inc  pipeline by indication  cyclacel pharmaceuticals inc  pipeline by stage of development  cyclacel pharmaceuticals inc  monotherapy products in pipeline  cyclacel pharmaceuticals inc  combination treatment modalities in pipeline  cyclacel pharmaceuticals inc  phase iii  cyclacel pharmaceuticals inc  phase ii  cyclacel pharmaceuticals inc  phase i  cyclacel pharmaceuticals inc  indcta filed  cyclacel pharmaceuticals inc  preclinical  cyclacel pharmaceuticals inc  discovery  cyclacel pharmaceuticals inc  pipeline by target  cyclacel pharmaceuticals inc  pipeline by route of administration  cyclacel pharmaceuticals inc  pipeline by molecule type  cyclacel pharmaceuticals inc  pipeline products by mechanism of action  cyclacel pharmaceuticals inc  recent pipeline updates  cyclacel pharmaceuticals inc  dormant developmental projects cyclacel pharmaceuticals inc other locations cyclacel pharmaceuticals inc subsidiaries list of figurescyclacel pharmaceuticals inc  pipeline by top  indication  cyclacel pharmaceuticals inc  pipeline by stage of development  cyclacel pharmaceuticals inc  monotherapy products in pipeline  cyclacel pharmaceuticals inc  pipeline by top  target  cyclacel pharmaceuticals inc  pipeline by top  route of administration  cyclacel pharmaceuticals inc  pipeline by top  molecule type  cyclacel pharmaceuticals inc  pipeline products by top  mechanism of action   companies mentioned in this reportcyclacel pharmaceuticals inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc cyclacel pharmaceuticals inc  cycc company news at ally invest quotes snapshot  cycccyclacel pharmaceuticals inc cyccnasdaqset alertoptionsstreaming chartslast pricenasdaq closing price as of pm et nasdaq minute delayed bidask quotestodays changebid size ask size day low  high  volume msellbuysnapshotchartsnewsoptionsearningsfundamentalsfinancialsinsiders cyclacel announces closing of  million underwritten public offering and full exercise of overallotment optionback to cycc snapshot share storypm et  globe newswireberkeley heights nj july   globe newswire  cyclacel pharmaceuticals inc nasdaqcycc cyclacel or the company a clinicalstage biopharmaceutical company using cell cycle transcriptional regulation and dna damage response biology to develop innovative targeted medicines for cancer and other proliferative diseases today announced the closing of an underwritten public offering of units for gross proceeds of  million which includes the full exercise of the underwriters overallotment option to purchase additional shares and warrants prior to deducting underwriting discounts and commissions and offering expenses payable by cyclacel existing and new investors participated in the offering the offering was comprised of class a units priced at a public offering price of  per unit each unit consisting of one share of common stock and a sevenyear warrant each a warrant to purchase one share of common stock with an exercise price of  per share and class b units priced at a public offering price of  per unit with each unit comprised of one share of preferred stock which is convertible into  shares of common stock and a warrant to purchase  shares of common stock also with an exercise price of  per share the conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed and do not contain any variable pricing features or any price based antidilutive features the preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights except to the extent that dividends are also paid on the common stock liquidation preference or other preferences over common stock and with certain exceptions has no voting rights the securities comprising the units were immediately separable and have been issued separately ladenburg thalmann  co inc a subsidiary of ladenburg thalmann financial services inc nyse mkt lts acted as sole bookrunning manager in connection with the offering a total of  shares of common stock  shares of preferred stock convertible into  shares of common stock and total warrants to purchase  shares of common stock were issued in the offering including the full exercise of the overallotment option if exercised in full the warrants could result in additional net financing proceeds to cyclacel of  million the securities were offered pursuant to a registration statement on form s file no  and an additional registration statement filed pursuant to rule b which was declared effective by the united states securities and exchange commission sec this press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sales of these securities in any jurisdiction in which such offer solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction a final prospectus relating to this offering has been filed by cyclacel with the sec copies of the final prospectus may be obtained at the secs website at wwwsecgov or from ladenburg thalmann  co inc prospectus department  park avenue th floor new york new york  by calling   about cyclacel pharmaceuticals inc cyclacel pharmaceuticals is a clinicalstage biopharmaceutical company using cell cycle transcriptional regulation and dna damage response biology to develop innovative targeted medicines for cancer and other proliferative diseases cyclacels transcriptional regulation program is evaluating cyc a cdk inhibitor in patients with advanced cancers the dna damage response program is evaluating a sequential regimen of sapacitabine and seliciclib a cdk inhibitor in patients with brca positive advanced solid cancers  cyclacel is analyzing stratified and exploratory subgroups from a phase  study of sapacitabine in elderly patients with aml cyclacels strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates for additional information please visit wwwcyclacelcom forwardlooking statements this news release contains certain forwardlooking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forwardlooking statements such forwardlooking statements include statements regarding among other things the efficacy safety and intended utilization of cyclacels product candidates the conduct and results of future clinical trials plans regarding regulatory filings future research and clinical trials and plans regarding partnering activities factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety andor efficacy in largerscale or later clinical trials trials may have difficulty enrolling cyclacel may not obtain approval to market its product candidates the risks associated with reliance on outside financing to meet capital requirements and the risks associated with reliance on collaborative partners for further clinical trials development and commercialization of product candidates you are urged to consider statements that include the words may will would could should believes estimates projects potential expects plans anticipates intends continues forecast designed goal or the negative of those words or other comparable words to be uncertain and forwardlooking for a further list and description of the risks and uncertainties the company faces please refer to our most recent annual report on form k and other periodic and other filings we file with the securities and exchange commission and are available at wwwsecgov such forwardlooking statements are current only as of the date they are made and we assume no obligation to update any forwardlooking statements whether as a result of new information future events or otherwise  copyright  cyclacel pharmaceuticals inc all rights reserved the cyclacel logo and cyclacel® are trademarks of cyclacel pharmaceuticals inc contacts company paul mcbarron   pmcbarroncyclacelcom investor relations russo partners llc alexander fudukidis   alexfudukidisrussopartnersllccom other top stories cycchouse of air adrenaline park to launch in carlsbadrivetz postpones decentralized cybersecurity token cshareholder alert goldberg law pc announces the filkeller rohrback llp investigates allegations of chagens berman wave of intellectual property lawsuit most popular storiescyclacel announces closing of  million underwricyclacel announces pricing of  million underwrimidday market update crude oil up over  cyclacfeuerstein showing concern with investorstraders geadam feuerstein sees major price manipulation in smamost popular keyword searchesspy goog ddd baba mjna fb znga amzn jcp enter symbol or name twtr amd f fnma kkd gpro bac aapl nflx tsla   cyclacel pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report cyclacel pharmaceuticals inc  product pipeline review   published by global markets direct product code  published august   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license cyclacel pharmaceuticals inc  product pipeline review   published august   content info  pages description summary global markets directs cyclacel pharmaceuticals inc  product pipeline review   provides an overview of the cyclacel pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of cyclacel pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of cyclacel pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of cyclacel pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the cyclacel pharmaceuticals incs pipeline products reasons to buy evaluate cyclacel pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of cyclacel pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the cyclacel pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of cyclacel pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of cyclacel pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of cyclacel pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures cyclacel pharmaceuticals inc snapshot cyclacel pharmaceuticals inc overview key information key facts cyclacel pharmaceuticals inc  research and development overview key therapeutic areas cyclacel pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities cyclacel pharmaceuticals inc  pipeline products glance cyclacel pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities cyclacel pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities cyclacel pharmaceuticals inc  early stage pipeline products indcta filed productscombination treatment modalities preclinical productscombination treatment modalities discovery productscombination treatment modalities cyclacel pharmaceuticals inc  drug profiles sapacitabine product description mechanism of action rd progress seliciclib product description mechanism of action rd progress sapacitabine  seliciclib product description mechanism of action rd progress cyc product description mechanism of action rd progress cyc product description mechanism of action rd progress cyclacel pharmaceuticals inc  pipeline analysis cyclacel pharmaceuticals inc  pipeline products by target cyclacel pharmaceuticals inc  pipeline products by route of administration cyclacel pharmaceuticals inc  pipeline products by molecule type cyclacel pharmaceuticals inc  pipeline products by mechanism of action cyclacel pharmaceuticals inc  recent pipeline updates cyclacel pharmaceuticals inc  dormant projects cyclacel pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables cyclacel pharmaceuticals inc key information cyclacel pharmaceuticals inc key facts cyclacel pharmaceuticals inc  pipeline by indication  cyclacel pharmaceuticals inc  pipeline by stage of development  cyclacel pharmaceuticals inc  monotherapy products in pipeline  cyclacel pharmaceuticals inc  combination treatment modalities in pipeline  cyclacel pharmaceuticals inc  phase iii  cyclacel pharmaceuticals inc  phase ii  cyclacel pharmaceuticals inc  phase i  cyclacel pharmaceuticals inc  indcta filed  cyclacel pharmaceuticals inc  preclinical  cyclacel pharmaceuticals inc  discovery  cyclacel pharmaceuticals inc  pipeline by target  cyclacel pharmaceuticals inc  pipeline by route of administration  cyclacel pharmaceuticals inc  pipeline by molecule type  cyclacel pharmaceuticals inc  pipeline products by mechanism of action  cyclacel pharmaceuticals inc  recent pipeline updates  cyclacel pharmaceuticals inc  dormant developmental projects cyclacel pharmaceuticals inc other locations cyclacel pharmaceuticals inc subsidiaries list of figures cyclacel pharmaceuticals inc  pipeline by top  indication  cyclacel pharmaceuticals inc  pipeline by stage of development  cyclacel pharmaceuticals inc  monotherapy products in pipeline  cyclacel pharmaceuticals inc  pipeline by top  target  cyclacel pharmaceuticals inc  pipeline by top  route of administration  cyclacel pharmaceuticals inc  pipeline by top  molecule type  cyclacel pharmaceuticals inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved cycc news  cyclacel pharmaceuticals inc company news  press releases  marketwatch bulletin investor alert tokyo markets open in us market snapshot currencies commodities expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close cyclacel pharmaceuticals inc nasdaq cycc go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus cyclacel pharmaceuticals inc after hours  quotes are delayed by  min jul    pm cycc quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   newslatestcompanyuscycc marketwatch news on cycc cyclacels stock plunges after disappointing trial results of its cancer treatment  am feb    tomi kilgore stemcells can’t fix its problems with a reverse split or by burying bad news  pm may    tomi kilgore ak steel drops after hours tibco surges  pm sept    wallace witkowski cyclacel reports positive results from cancer drug  pm sept    marketwatchcom drug stocks join in broader market rally  pm july    val brickates kennedy cyclacel tumbles  on stock offering  am july    val brickates kennedy drug stocks follow celgene south  pm dec    val brickates kennedy drug indexes split orexigen slides  pm dec    val brickates kennedy cyclacel rallies on drug update  am dec    val brickates kennedy nasdaq hesitates at the day moving average  am feb    michael ashbaugh staking out the sp s new trading range  am feb    michael ashbaugh stocks in focus for thursday  pm aug    marketwatch needham sets cyclacel pharma price target at   am july    tomi kilgore cyclacel pharma started at buy at needham  am july    tomi kilgore newsnonmarketwatchcompanyuscycc other news on cycc daily insider ratings round up  sanw le olbk  am today am july    seeking alpha cyclacel prices equity offering shares down  premarket  am july    seeking alpha cyclacel readies equity offering shares down  premarket  am july    seeking alpha q cyclacel pharmaceuticals inc  pm may    edgar online  edg  q k cyclacel pharmaceuticals cycc ceo spiro rombotis on q  results  earnings call transcript  pm may    seeking alpha cyclacel pharma q loss narrows shares up  after hours on encouraging earlystage data on cyc  pm may    seeking alpha lose money now ask me how  pm april    seeking alpha company news for april    am april    zackscom rising biotechs paratek among stocks surging on trial results  pm april    investors business daily premarket gainers as of  am  am april    seeking alpha cyclacels next gen cdk inhibitor cyc shows antitumor effect in preclinical testing shares ahead   am april    seeking alpha cyclacel pharmaceuticals cycc ceo spiro rombotis on q  results  earnings call transcript  pm march    seeking alpha cyclacel pharmaceuticals is there anything left in the tank  pm march    seeking alpha cyclacels cdk inhibitors show antitumor effect against lung cancer in preclinical testing  am march    seeking alpha insiderinsightscom daily round up  uihc gnc asps jmba  am march    seeking alpha snippet roundup cyclacels data dredge and bristols activist investor  am feb    seeking alpha cyclacels lead product candidate flunks latestage leukemia study shares down  premarket  am feb    seeking alpha cyclacel pharmaceuticals cycc presents at biotech showcase conference  pm jan    seeking alpha biggest movers in manufacturing stocks now – myov elgx bmra ivac  pm dec    investorplacecom  biotechnology stocks to sell now  am dec    investorplacecom loading more headlines newspressreleasecompanyuscycc press releases on cycc cyclacel announces closing of  million underwritten public offering and full exercise of overallotment option  pm july    globenewswire todays research reports on trending tickers cyclacel pharmaceuticals inc and canadian solar inc  am july    accesswire cyclacel announces pricing of  million underwritten public offering  am july    globenewswire todays research report coverage on biotech stocks  cyclacel pharma cytori therapeutics la jolla pharma and moleculin biotech  am june    pr newswire  prf cyclacel pharmaceuticals reports first quarter  financial results  pm may    globenewswire investor network cyclacel pharmaceuticals inc to host earnings call  pm may    accesswire cyclacel pharmaceuticals to release first quarter  financial results  am may    globenewswire todays research reports on biotech stocks to watch brainstorm cell therapeutics and cyclacel pharmaceuticals  am april    accesswire cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk inhibitor cyc  pm april    globenewswire novocure and cyclacel pharmaceuticals surge on positive fda trial news  am april    accesswire cyclacels secondgeneration cdk inhibitor cyc elicits marked antineoplastic effects in lung cancer by engaging antimetastatic pathways  pm april    globenewswire cyclacel pharmaceuticals reports fourth quarter and full year  financial results  pm march    globenewswire cyclacel pharmaceuticals to release fourth quarter and full year  financial results  am march    globenewswire cyclacels cdk inhibitor cyc causes anaphase catastrophe a novel cancerspecific mechanism of action in research published in jnci  am march    globenewswire cyclacel announces topline results from pivotal phase  seamless study in elderly patients with acute myeloid leukemia  am feb    globenewswire cyclacel pharmaceuticals to present at the th annual bio ceo  investor conference  am feb    globenewswire anthera announces leadership transition in preparation of commercialization of sollpura and future development of blisibimod for iga nephropathy  pm dec    globenewswire cyclacels novel plk inhibitor cyc demonstrates therapeutic potential in esophageal cancer and acute leukemia  am dec    globenewswire cyclacel pharmaceuticals reports rd quarter  financial results  pm nov    globenewswire cyclacel pharmaceuticals to release third quarter  financial results  am nov    globenewswire loading more headlines log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pfed to stick to plans for rate hike balancesheet selloff this year pmls says no to promotionandrelegation regime — and  billion to boot pbitcoin platform scores key greenlight from wall street regulator palphabet falls after earnings beat live blog recap pis kushners statement a turning point for trump team pis this why united tsa clashed on twitter over comic books on planes pyear treasury yield snaps sixday streak of declines pcompanies do better when ceo pay dwarfs average worker study finds panadarko shares down  after company posts widerthanexpected loss palphabet falls after earnings beat live blog ptrump pushes gop for affordable care act repeal pus will go singlepayer route on health care jimmy carter pthe scientifically proven reason you should stop feeling guilty about ordering takeout pnasdaq closes at record as tech stocks shake off broader weakness pwatch out for these surprise charges at the er phere’s a sign investors are viewing earnings through rosetinted glasses popinion journal congresss russia sanctions calculus popinion journal robert mueller’s power play popinion journal joseph rago popinion journal americans abroad beware loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  cyclacel pharmaceuticals inc  biopharmaceutical company developing cell cycle control cancer therapies cell cycle pioneers improving patients healthcare with orally available innovative medicines cyclacel pharmaceuticals inc nasdaq cycc nasdaq cyccp is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases our pipeline applying its core strength in cell cycle biology cyclacel is advancing a pipeline of orally available small molecule investigational drugs designed to stop uncontrolled cell division sapacitabine our lead drug candidate is being evaluated in the seamless pivotal phase  trial in elderly patients with acute myeloid leukemia under a special protocol assessment agreement with the us food and drug administration for more information on our investigational drug programs and clinical trials please go to the research  development tab above learn more about our clinical trials sapacitabine cyc an oral nucleoside analogue prodrug that acts through a novel mechanism seliciclib cyc a novel firstinclass orally available cyclin dependent kinase cdk inhibitor cyc a highlyselective orallyavailable nd generation inhibitor of cyclin dependent kinases cdk  and  perspectives sapacitabine patient seliciclib patient investigator details common stock info nasdaqcm cycc us delayed at least  minutes provided by esignal healtheo presents exchange  a conversation with spiro rombotis from cyclacel acute myeloid leukemia watch the video on the healtheo website yelp yelp sorry you’re not allowed to access this page contact yelp if you keep experiencing issues bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one